jnj-39220675
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00804687)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H3 receptorANTAGONIST
Histamine H3 receptor antagonist
Also inhibits the serotonin transporter.
- Histamine H3 receptorINHIBITOR
HRH3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(c1ccc(Oc2ccc(F)cc2)nc1)N1CCCN(C2CCC2)CC1- Mol. weight
- 369.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1171754 ↗
Also known as
- (4-cyclobutyl-(1,4)diazepan-1-yl)-(6-(4-fluorophenoxy)pyridin-3-yl)methanone
- jnj39220675
- jnj 39220675
- jnj-39220675
- jnj-39220675
- jnj-39220675
- jnj-39220675
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00804687 | Phase 2 | Nov 1, 2008 | Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2008 |
1 organizations
Page 1 / 1